文献速递血管炎

托珠单抗治疗颅型和颅外型巨细胞动脉炎:一项纳入471例患者的全国多中心研究

Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该多中心观察性研究纳入471例接受托珠单抗治疗的巨细胞动脉炎(GCA)患者,分为颅型(cGCA)、颅外型(ecGCA)和混合型(mixGCA)三种表型。结果显示托珠单抗在各表型中均能快速且持续地实现临床缓解和EULAR完全缓解,但ecGCA和mixGCA的影像学无炎症比例远低于cGCA,109例(23.1%)出现相关不良事件。

要点

  • 托珠单抗在各GCA表型中1个月和24个月均显示快速且持续的临床缓解及EULAR完全缓解。
  • ecGCA和mixGCA在24个月时影像学无炎症的比例远低于cGCA。
  • 109例(23.1%)患者出现相关不良事件。

核心结论

  • 托珠单抗在所有GCA表型中均能快速且持续地实现临床缓解和EULAR完全缓解。
  • ecGCA和mixGCA的影像学无炎症比例远低于cGCA。

研究设计与样本

  • 多中心观察性研究,纳入471例接受托珠单抗治疗的GCA患者,分为cGCA(n=217;46%)、mixGCA(n=174;37%)和ecGCA(n=80;17%)三种表型。

主要发现

  • ecGCA患者年龄(66.5±10.1岁)小于cGCA(74.8±8.1岁)和mixGCA(71.4±8.5岁),且GCA诊断延迟更长(中位[IQR]分别为6(1-14)vs 1(1-3)vs 2(1-6)个月)。
  • 全身表现三组相似,缺血表现以cGCA更常见。
  • 联合托珠单抗(在糖皮质激素基础上)在ecGCA中使用更多(36%)。
  • 临床缓解在cGCA/ecGCA/mixGCA中分别为第1个月51%/43%/47%,第24个月79%/81%/89%。
  • EULAR完全缓解在cGCA/ecGCA/mixGCA中分别为第1个月35%/27%/28%,第24个月72%/73%/67%。

关键数值与推荐

  • 临床缓解:cGCA/ecGCA/mixGCA第1个月分别为51%/43%/47%,第24个月分别为79%/81%/89%。
  • EULAR完全缓解:cGCA/ecGCA/mixGCA第1个月分别为35%/27%/28%,第24个月分别为72%/73%/67%。
  • 影像学无炎症:ecGCA/mixGCA第12个月分别为15%/26%,第24个月分别为22%/7%。
  • 相关不良事件:109例(23.1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The spectrum of GCA includes various vascular phenotypes. Tocilizumab (TCZ) is the only biologic therapy currently approved, regardless of phenotype. We aimed to assess the effectiveness of TCZ in various phenotypes. METHODS: This is a multicentre observational study of GCA patients treated with TCZ. They were divided into three phenotypes: (i) cranial (cGCA), (ii) extracranial GCA (ecGCA) and (iii) mixed GCA (mixGCA). Outcomes included clinical remission, EULAR complete remission, relapses, absence of inflammation as shown using imaging techniques, and safety. RESULTS: We studied 471 patients (342 women; mean age 74.0 ± 9.0 years). The phenotypic distribution was: cGCA (n = 217; 46%), mixGCA (174; 37%) and ecGCA (80; 17%). Patients with ecGCA were younger (66.5 ± 10.1 years) than those with cGCA (74.8 ± 8.1) and those with mixGCA (71.4 ± 8.5), and had a longer delayed GCA diagnosis {median [interquartile range (IQR) [6 (1-14)] vs 1 (1-3) vs 2 (1-6) months, respectively}. Systemic manifestations were similar in the three groups, while ischaemic manifestations were more frequent in cGCA. Combined TCZ, in addition to glucocorticoids, was used more frequently in ecGCA (36%). Clinical remission was observed in 51%/43%/47% in cGCA/ecGCA/mixGCA, respectively, after the first month, and in 79%/81%/89% after 24 months. Complete EULAR remission in 35%/27%/28% (after 1 month) and 72%/73%/67% (after 24 months). Absence of inflammation being shown in the imaging techniques was 15%/26% after 12 months, and 22%/7% (ecGCA/mixGCA) (after 24 months). Relevant adverse events were observed in 109 (23.1%) patients. CONCLUSION: TCZ shows rapid and maintained effectiveness in all GCA phenotypes in clinical remission and EULAR complete remission. By contrast, absence of inflammation as shown using imaging techniques was much lower in ecGCA and mixGCA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Blanco R, Aldasoro V, Maiz O, et al. Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases. Rheumatology (Oxford). 2025. PMID: 39658241. doi:10.1093/rheumatology/keae666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。